Hudson Bay Capital Management LP Has $4.62 Million Stake in Arcus Biosciences, Inc. $RCUS

Hudson Bay Capital Management LP decreased its holdings in Arcus Biosciences, Inc. (NYSE:RCUS) by 20.9% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 340,000 shares of the company’s stock after selling 90,000 shares during the quarter. Hudson Bay Capital Management LP owned approximately 0.31% of Arcus Biosciences worth $4,624,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of RCUS. Geode Capital Management LLC raised its holdings in shares of Arcus Biosciences by 14.9% in the second quarter. Geode Capital Management LLC now owns 1,596,329 shares of the company’s stock valued at $12,995,000 after buying an additional 207,097 shares during the last quarter. SG Americas Securities LLC grew its holdings in Arcus Biosciences by 166.9% during the 2nd quarter. SG Americas Securities LLC now owns 27,362 shares of the company’s stock worth $223,000 after acquiring an additional 17,111 shares during the last quarter. Candriam S.C.A. acquired a new stake in Arcus Biosciences in the 3rd quarter valued at about $5,147,000. Tema Etfs LLC increased its position in Arcus Biosciences by 291.2% in the 2nd quarter. Tema Etfs LLC now owns 59,662 shares of the company’s stock valued at $486,000 after acquiring an additional 44,411 shares in the last quarter. Finally, Decheng Capital LLC raised its stake in shares of Arcus Biosciences by 242.3% in the third quarter. Decheng Capital LLC now owns 547,609 shares of the company’s stock worth $7,447,000 after acquiring an additional 387,609 shares during the last quarter. Institutional investors and hedge funds own 92.89% of the company’s stock.

Arcus Biosciences Trading Down 3.3%

Shares of NYSE RCUS opened at $21.69 on Friday. Arcus Biosciences, Inc. has a fifty-two week low of $6.50 and a fifty-two week high of $26.40. The firm has a market capitalization of $2.72 billion, a P/E ratio of -6.57 and a beta of 0.85. The company has a debt-to-equity ratio of 0.16, a current ratio of 4.36 and a quick ratio of 4.36. The company’s 50 day simple moving average is $21.56 and its 200 day simple moving average is $19.80.

Arcus Biosciences (NYSE:RCUS) last issued its earnings results on Wednesday, February 25th. The company reported ($0.89) EPS for the quarter, beating the consensus estimate of ($1.11) by $0.22. Arcus Biosciences had a negative net margin of 142.91% and a negative return on equity of 65.77%. The company had revenue of $33.00 million during the quarter, compared to analysts’ expectations of $24.94 million. During the same quarter in the previous year, the company posted ($1.03) EPS. The business’s revenue for the quarter was down 8.3% compared to the same quarter last year. On average, analysts predict that Arcus Biosciences, Inc. will post -3.15 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the stock. The Goldman Sachs Group upgraded shares of Arcus Biosciences from a “neutral” rating to a “buy” rating and upped their target price for the stock from $16.00 to $28.00 in a research report on Monday, January 12th. Wells Fargo & Company set a $23.00 price objective on shares of Arcus Biosciences and gave the stock an “equal weight” rating in a research report on Thursday, February 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arcus Biosciences in a report on Wednesday, January 21st. Morgan Stanley reiterated an “equal weight” rating and issued a $20.00 price objective (down from $23.00) on shares of Arcus Biosciences in a research report on Thursday, January 8th. Finally, HC Wainwright reissued a “buy” rating and issued a $32.00 target price on shares of Arcus Biosciences in a research note on Monday, March 2nd. Eight research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Arcus Biosciences has an average rating of “Moderate Buy” and an average price target of $30.20.

Insider Transactions at Arcus Biosciences

In related news, President Juan C. Jaen sold 31,823 shares of Arcus Biosciences stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $21.41, for a total transaction of $681,330.43. Following the transaction, the president owned 922,240 shares of the company’s stock, valued at $19,745,158.40. This trade represents a 3.34% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Robert C. Goeltz II sold 6,552 shares of the company’s stock in a transaction that occurred on Wednesday, December 31st. The shares were sold at an average price of $23.38, for a total transaction of $153,185.76. Following the completion of the sale, the chief financial officer directly owned 67,924 shares of the company’s stock, valued at $1,588,063.12. The trade was a 8.80% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 9.60% of the stock is currently owned by company insiders.

Arcus Biosciences Company Profile

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.